-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Immunome, Raises Price Target to $38

Benzinga·08/12/2026 17:27:28
Listen to the news
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.